Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.
Uses biomarker-based patient selection to develop precision psychiatric drugs matched to specific patient subtypes.
Pre-revenue: it sells nothing, and trial costs are paid from cash raised since its early-2024 listing. Each drug is tested only in patients whose brain-activity or other markers match, so the results of those mid-stage depression trials, not sales, decide the company's course.
Moat: narrow (data, process know-how). Proprietary biomarker/EEG-based patient stratification aims to improve historically poor psychiatric trial success rates.
Headquarters: Los Altos, California, US · Founded: 2019 · Employees: 68
Size Alto Neuroscience (ANRO) is a United States Health Care company (Biotechnology) with a market value of $1.04B, the 2208th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.91 on 18 Nov 2026.
Performance Over six months the shares gained 24.7%, against -16.6% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Short interest Short interest is 14.5% of the free float (30 Oct 2026).
Next results Next results expected around 24 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$641,000 | -$661,000 | -$502,000 | -$373,000 | -$342,000 |
| EBITDA | -$99.5M | -$65.7M | -$68.1M | -$37.4M | -$28.9M |
| Net income | -$95.2M | -$63.2M | -$61.4M | -$36.3M | -$27.7M |
| Free cash flow | -$79.7M | -$51.8M | -$49.5M | -$33.9M | -$21.1M |
| Capital expenditure | $556,000 | $24,000 | $2.08M | $470,000 | $732,000 |
| Total debt | $18.0M | $24.0M | $16.9M | $151M | $82.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Alto Neuroscience ANRO | $1.04B | +25% | n/a | n/a | n/a | n/a |
| Neurocrine Biosciences NBIX | $16.5B | +5% | +38% | 25% | 4.4× | -1.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANRO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.2% | -8.6% | 2nd highest of 21 |
| 6-month return | +24.7% | -16.6% | 3rd highest of 20 |
| Distance from 52-week high | -30.9% | -40.8% | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% | -7.0% |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 3.5× | n/a | n/a |